title: Inhibition of phosphotidylinositol-3 kinase pathway by a novel naphthol derivative of betulinic acid induces cell cycle arrest and apoptosis in cancer cells of different origin.
abstract: Betulinic acid (BA) is a pentacyclic triterpenoid natural product reported to inhibit cell growth in a variety of cancers. However, the further clinical development of BA got hampered because of poor solubility and pharmacological properties. Interestingly, this molecule offer several hotspots for structural modifications in order to address its associated issues. In our endeavor, we selected C-3 position for the desirable chemical modification in order to improve its cytotoxic and pharmacological potential and prepared a library of different triazoline derivatives of BA. Among them, we previously reported the identification of a potential molecule, that is, 3{1N(5-hydroxy-naphth-1yl)-1H-1,2,3-triazol-4yl}methyloxy betulinic acid (HBA) with significant inhibition of cancer cell growth and their properties. In the present study, we have shown for the first time that HBA decreased the expression of phosphotidylinositol-3 kinase (PI3K) p110α and p85α and caused significant downregulation of pAKT and of NFκB using human leukemia and breast cancer cells as in vitro models. Further it was revealed that PI3K inhibition by HBA induced cell cycle arrest via effects on different cell cycle regulatory proteins that include CDKis cyclins and pGSK3β. Also, this target-specific inhibition was associated with mitochondrial apoptosis as was reflected by the increased expression of mitochondrial bax, downregulated bcl2 and decreased mitochondrial levels of cytochrome c, together with reactive oxygen species generation and decline in mitochondrial membrane potential. The apoptotic effectors such as caspase 8, caspase 9 and caspase 3 were found to be upregulated besides DNA repair-associated enzyme, that is, PARP cleavage caused cancer cell death. Pharmacodynamic evaluation revealed that both HBA and BA were safe upto the dose of 2000 mg/kg body weight and with acceptable pharmacodynamic parameters. The in vitro data corroborated with in vivo anticancer activity wherein Ehrlich solid tumor showed that HBA as a more potent agent than BA without any body weight loss and mortality.
authors.affiliation: 1] Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India [2] Bio-organic Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
authors.forename: R
authors.initials: R
authors.lastname: Majeed
authors.affiliation: Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
authors.forename: A
authors.initials: A
authors.lastname: Hamid
authors.affiliation: Bio-organic Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
authors.forename: P L
authors.initials: PL
authors.lastname: Sangwan
authors.affiliation: Bio-organic Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
authors.forename: P K
authors.initials: PK
authors.lastname: Chinthakindi
authors.affiliation: Bio-organic Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
authors.forename: S
authors.initials: S
authors.lastname: Koul
authors.affiliation: PK-PD Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
authors.forename: S
authors.initials: S
authors.lastname: Rayees
authors.affiliation: PK-PD Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
authors.forename: G
authors.initials: G
authors.lastname: Singh
authors.affiliation: Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
authors.forename: D M
authors.initials: DM
authors.lastname: Mondhe
authors.affiliation: Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
authors.forename: M J
authors.initials: MJ
authors.lastname: Mintoo
authors.affiliation: Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
authors.forename: S K
authors.initials: SK
authors.lastname: Singh
authors.affiliation: Bio-organic Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
authors.forename: S K
authors.initials: SK
authors.lastname: Rath
authors.affiliation: Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
authors.forename: A K
authors.initials: AK
authors.lastname: Saxena
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D059447:Cell Cycle Checkpoints / Q000187:drug effects*; D045744:Cell Line, Tumor; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D006801:Humans; D015394:Molecular Structure; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D053978:Pentacyclic Triterpenes; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics / Q000378:metabolism*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D014315:Triterpenes / Q000737:chemistry / Q000494:pharmacology*; D000094062:Betulinic Acid
chemical_list: D004791:Enzyme Inhibitors; D053978:Pentacyclic Triterpenes; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D014315:Triterpenes; D000094062:Betulinic Acid